|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||7.71 - 7.80|
|52 Week Range||7.40 - 17.20|
|Beta (5Y Monthly)||0.67|
|PE Ratio (TTM)||11.26|
|Forward Dividend & Yield||0.17 (1.88%)|
|Ex-Dividend Date||Sept 22, 2021|
|1y Target Est||N/A|
Full Year 2022 Aspen Pharmacare Holdings Ltd Earnings Call
Aspen Pharmacare has signed a deal with the Serum Institute of India to manufacture and sell four Aspen-branded vaccines for Africa, as it seeks to utilise its near-idle COVID-19 vaccine production lines in eastern South Africa. Aspen has a contract with Johnson & Johnson to package its COVID-19 vaccine into vials and earlier this year it extended its agreement to allow it to package, sell and distribute the vaccine under its own brand Aspenovax for Africa. But it has not received a single order yet for the COVID vaccine and its J&J orders under its previous contract were also "dwindling", putting at risk its 450-million-dose vaccine production line.
Africa's top public health body said on Thursday it was hopeful South African pharmaceutical firm Aspen Pharmacare would get orders for its own brand COVID-19 vaccine. Africa Centers for Disease Control and Prevention (CDC) said last month that it is in detailed discussions with buyers to generate demand for Aspen's COVID-19 vaccine Aspenovax. Just one fifth of adults in Africa are fully vaccinated against COVID-19, but demand has fallen across the continent which already receives donated vaccines from Western countries and has supplies to hand from earlier purchases.